Privi Speciality Chemicals reported a strong second quarter for FY27 with a 24.6% jump in net profit to INR 117.03 crore. The company announced its maiden interim dividend of INR 5 per share alongside robust income growth of 13.9%.
Privi Speciality Chemicals Q2 Profit Jumps 24.6% to INR 117.03 Crore
Privi Speciality Chemicals reported a Profit After Tax of INR 117.03 crore for Q2 FY27, representing a 24.61% increase year-on-year.
Total income for the quarter grew by 13.9% to INR 773.16 crore, supported by improved operational efficiency.
Reader Takeaway: Strong profit growth and maiden dividend signal health, though regulatory hurdles for Phase 2 expansion remain key.
What just happened
The board of directors declared the company's first-ever interim dividend of INR 5 per share. Financial performance improved across the board, with EBITDA rising 16.66% to INR 212.49 crore. The company successfully reduced its working capital cycle to under 100 days from 124 days previously.
Why this matters
The steady deleveraging of the balance sheet is a critical indicator of financial discipline. With a net debt-to-EBITDA ratio of 1.07x and net debt-to-equity at 0.51x as of September 30, 2026, the company is positioning itself for sustained growth. Management has set a long-term revenue target of INR 5,000 crore by 2030.
Expansion Update
Phase 1 of the capacity expansion is complete, raising capacity to 54,000 MTPA. The management outlined a total three-phase capital expenditure plan of INR 1,400 crore. Phase 2, which includes products like Maltol and Ethyl Maltol, is slated for commercial sales in the second half of the next financial year.
Risks to watch
Success for future growth hinges on securing pending regulatory approvals for the Phase 2 expansion. Furthermore, while margins have been stable, the business remains exposed to potential volatility in raw material costs, freight charges, and ongoing geopolitical tensions that impact global supply chains.
What to track next
Investors should monitor the timeline for Phase 2 regulatory clearances and the production ramp-up for the new product pipeline. Additionally, the continued performance of the Prigiv joint venture, which recently hit consistent profitability, will be a point of interest for long-term margin trends.
